Treatments and associated outcomes of acral lentiginous melanoma: A review - 19/06/20
Doi : 10.1016/j.jaad.2019.11.021
Marissa B. Lobl, BS, BBA a 
, Chelsea Santos, MPH b, Dillon Clarey, MD a, Shauna Higgins, MD a, c, Edibaldo Silva-Lopez, MD, PhD d, Adam Sutton, MD, MBA a, Ashley Wysong, MD, MS a, c, ⁎
, Chelsea Santos, MPH b, Dillon Clarey, MD a, Shauna Higgins, MD a, c, Edibaldo Silva-Lopez, MD, PhD d, Adam Sutton, MD, MBA a, Ashley Wysong, MD, MS a, c, ⁎ a Department of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska
b School of Medicine, University of California-Riverside, Riverside, California
c Keck School of Medicine, University of Southern California, Los Angeles, California
d Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska
∗Reprint requests: Ashley Wysong, MD, MS, 985645 Nebraska Medical Center, Omaha, NE 68198-5645985645 Nebraska Medical CenterOmahaNE68198-5645
| Funding sources: None. |
|
| Conflicts of interest: Dr Wysong serves as an unpaid advisor to Castle Biosciences. All other authors have no conflicts of interest to declare. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 1
P. 230-234 - juillet 2020 Retour au numéro
Article précédent
- When the treatment is the culprit: Prevalence of allergens in prescription topical steroids and immunomodulators
- Jennifer M. Tran, Margo J. Reeder
- Improved survival for skin-primary presentation of adult T-cell leukemia/lymphoma (ATLL)
- Meera Jain, Kavita Goyal, Daniel O'Leary, Nathan Rubin, Kimberly Bohjanen, Amrita Goyal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?